Roche Expands PCR-Test Portfolio with Completion of Purchase Agreement of TIB Molbiol
The companies will focus on the rapid development of polymerase chain reaction assays for emerging pathogens and potential health threats, including biological threats.
On Dec. 1, 2021, Roche announced the completion of its share purchase agreement to acquire 100% of the outstanding shares of TIB Molbiol Group in a company press release. The companies will focus on the rapid development of polymerase chain reaction (PCR) assays and diagnostic tests for emerging pathogens and potential health threats, such as infectious diseases. TIB Molbiol will operate as a subsidiary within the Diagnostics division.
For more than 20 years, the companies have collaborated to address biological threats, including:
- SARS
- Anthrax
- Avian influenza virus H5N1
- MERS
- The novel influenza virus H1N1 swine
- Ebola virus
- Zika virus
- SARS-CoV-2 virus and its variants.
“I am very pleased that together with TIB Molbiol, we can significantly improve access for patients to a broader spectrum of diagnostic tests—from high volume routine tests to the diagnosis of rare diseases. TIB Molbiol will continue to be an innovation engine and frontrunner in our common fight against infectious diseases, such as SARS-CoV-2,” said Thomas Schinecker, CEO, Roche Diagnostics, in a company press release. “TIB Molbiol has helped to shape the future of PCR infectious disease testing and will continue to drive cutting-edge research so we can bring better healthcare outcomes to patients faster.”
Source: Roche
